1. Home
  2. CERO vs SOBR Comparison

CERO vs SOBR Comparison

Compare CERO & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • SOBR
  • Stock Information
  • Founded
  • CERO 2017
  • SOBR 2004
  • Country
  • CERO United States
  • SOBR United States
  • Employees
  • CERO N/A
  • SOBR N/A
  • Industry
  • CERO
  • SOBR Newspapers/Magazines
  • Sector
  • CERO
  • SOBR Consumer Discretionary
  • Exchange
  • CERO Nasdaq
  • SOBR Nasdaq
  • Market Cap
  • CERO 6.1M
  • SOBR 5.2M
  • IPO Year
  • CERO N/A
  • SOBR N/A
  • Fundamental
  • Price
  • CERO $5.39
  • SOBR $3.35
  • Analyst Decision
  • CERO Strong Buy
  • SOBR
  • Analyst Count
  • CERO 2
  • SOBR 0
  • Target Price
  • CERO $45.00
  • SOBR N/A
  • AVG Volume (30 Days)
  • CERO 82.8K
  • SOBR 15.1K
  • Earning Date
  • CERO 11-18-2025
  • SOBR 11-13-2025
  • Dividend Yield
  • CERO N/A
  • SOBR N/A
  • EPS Growth
  • CERO N/A
  • SOBR N/A
  • EPS
  • CERO N/A
  • SOBR N/A
  • Revenue
  • CERO N/A
  • SOBR $301,400.00
  • Revenue This Year
  • CERO N/A
  • SOBR N/A
  • Revenue Next Year
  • CERO N/A
  • SOBR N/A
  • P/E Ratio
  • CERO N/A
  • SOBR N/A
  • Revenue Growth
  • CERO N/A
  • SOBR 73.21
  • 52 Week Low
  • CERO $4.27
  • SOBR $2.41
  • 52 Week High
  • CERO $895.40
  • SOBR $193.50
  • Technical
  • Relative Strength Index (RSI)
  • CERO 40.84
  • SOBR 47.95
  • Support Level
  • CERO $5.18
  • SOBR $3.18
  • Resistance Level
  • CERO $5.45
  • SOBR $3.54
  • Average True Range (ATR)
  • CERO 0.24
  • SOBR 0.13
  • MACD
  • CERO 0.09
  • SOBR 0.00
  • Stochastic Oscillator
  • CERO 56.96
  • SOBR 43.59

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

Share on Social Networks: